---
title: "Key facts: APRE APR‑1051, ATRN‑119 progress; Q1 loss $0.22"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286379412.md"
description: "APRE reported a Q1 adjusted loss of $0.22 per share with a net loss of $3.29 million and no revenue. The company’s APR-1051 showed partial responses in endometrial cancer, while ATRN-119 reached Phase 2 at a 1,100 mg dose. The stock rose 18% this quarter and 5.5% year-to-date, with a median 12-month target of $5.2 and a 27% increase in mean earnings estimates over the past three months. Cash runway extends into Q1 2028, with APR-1602 IND studies planned for late 2026."
datetime: "2026-05-14T07:54:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286379412.md)
  - [en](https://longbridge.com/en/news/286379412.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286379412.md)
---

# Key facts: APRE APR‑1051, ATRN‑119 progress; Q1 loss $0.22

-   APRE: APR-1051 showed partial responses in PPP2R1A‑mutated endometrial cancer; ATRN‑119 found Phase 2 dose 1,100 mg; APR‑1602 IND studies slated late 2026; cash runway into Q1 2028.1
-   APRE reported Q1 adjusted loss $0.22/share, revenue $0, net loss $3.29M. Stock +18% this quarter, +5.5% YTD. Mean earnings estimate up ~27% past 3 months; median 12‑month target $5.2

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Aprea Therapeutics Q1 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/286243183.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)